10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $165.02 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.03% ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...